DRRX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	33 436.00
Average Volume	163 732
Market Cap	28.43M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $-0.210 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.760
ATR14	$0.0120 (1.31%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-21	Robertson Judith J.	Buy	5 500	Stock Option (right to buy)
2023-06-21	Maderis Gail J	Buy	5 500	Stock Option (right to buy)
2023-06-21	Garcia Peter S	Buy	5 500	Stock Option (right to buy)
2023-06-21	Farfel Gail M	Buy	5 500	Stock Option (right to buy)
2023-06-21	Blaschke Terrence F	Buy	5 500	Stock Option (right to buy)

INSIDER POWER
99.17
Last 97 transactions
Buy: 5 988 954 \| Sell: 1 498 606

DURECT Corp Correlation

10 Most Positive Correlations
APOP	0.917
RMRM	0.903
GAINL	0.885
KTRA	0.87
TDAC	0.859
PASG	0.858
VXRT	0.853
ADMA	0.851
GLMD	0.846
VVOS	0.841

10 Most Negative Correlations
BOCH	-0.926
MMAC	-0.878
SHSP	-0.857
NETE	-0.855
DSPG	-0.837
LINK	-0.824

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

DURECT Corp Financials

Annual	2023
Revenue:	$8.55M
Gross Profit:	$6.83M (79.91 %)
EPS:	$-1.050

FY	2023
Revenue:	$8.55M
Gross Profit:	$6.83M (79.91 %)
EPS:	$-1.050

FY	2022
Revenue:	$19.28M
Gross Profit:	$17.70M (91.76 %)
EPS:	$-1.560

FY	2021
Revenue:	$13.98M
Gross Profit:	$12.02M (86.01 %)
EPS:	$-0.0161

Financial Reports:

No articles found.

DURECT Corp

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.